Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02726386 · ClinicalTrials.gov registry record · Phase 2

A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease

A Phase 2 study of Parkinson's Disease, sponsored by NeuroDerm.

Active
Registry status
Phase 2
Development phase
214
Enrollment target
20
Study locations

NCT02726386 is a Phase 2 study of Parkinson's Disease that is active but no longer recruiting, run by NeuroDerm. The registered enrollment target is 214 participants, below the 641-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02726386, a Phase 2 study of Parkinson's Disease, is active but no longer recruiting, sponsored by NeuroDerm.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
214 participants
Enrollment target
20
Study locations

Study Summary

This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in subjects with advanced Parkinson's Disease (PD).

Conditions Studied

Parkinson's Disease

Interventions

  • DRUG ND0612

Study Locations (20)

Florida

  • Parkinson's Disease and Movement Disorder Center of Boca Raton - Boca Raton
  • MD Clinical - Hallandale
  • Infinity Clinical Research, LLC - Hollywood
  • University of Florida Health at Jacksonville - Jacksonville
  • Neurology Associates, PA - Maitland
  • Parkinsons Disease Treatment Center of Southwest Florida - Port Charlotte
  • Suncoast Neuroscience Associates - St. Petersburg
  • Infinity Clinical Research, LLC - Sunrise
  • USF Health Parkinson's Disease and Movement Disorders - Tampa

California

  • The Parkinsons and Movement Disorder Institute - Fountain Valley
  • Neuro Pain Medical Center - Fresno

Colorado

  • University of Colorado Denver - Aurora
  • Rocky Mountain Movement Disorders Center - Englewood

Michigan

  • QUEST Research Institute - Farmington Hills
  • Henry Ford Hospital - West Bloomfield

Arizona

  • Xenoscience - Phoenix

Arkansas

  • Clinical Trials Inc. - Little Rock

Illinois

  • Northwestern University - Chicago

Iowa

  • Unity Point Health - Des Moines

Trial Details

FieldValue
Enrollment Target 214 participants
Start Date 2016-05-04
Est. Completion 2027-02
Phase Phase 2

Sponsor

NeuroDerm

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02726386

The ClinicalTrials.gov registry entry for NCT02726386 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 641-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (67% lower). The listed sponsor is NeuroDerm, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which ND0612 is the first listed.

NCT02726386 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT02726386 about?

NCT02726386 is a clinical study titled "A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease". This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in subjects with advanced Parkinson's Disease (PD).

What is the current status of trial NCT02726386?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 214 participants. The study started on 2016-05-04. Estimated completion is 2027-02.

What conditions does trial NCT02726386 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT02726386?

The interventions under investigation include: ND0612 (DRUG).

Who is sponsoring clinical trial NCT02726386?

This trial is sponsored by NeuroDerm, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02726386 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.